Radical cystectomy (RC) with lymph node (LN) dissection (LND), eventually preceded by neoadjuvant chemotherapy, represents the standard treatment for muscle-invasive (MIBC) and very-high-risk non-muscle-invasive bladder cancer (NMIBC) patients. LND is a fundamental step of the surgical procedure, being able to provide staging information essential for decision-making about adjuvant therapies and follow up, and to improve oncological outcomes. One of the main dilemmas about LND regards its extent; recently, the first randomized controlled trial comparing different templates of LND did not find any difference in terms of perioperative and oncological outcomes between extended and super-extended LND. However, some limitations of the study and retrospective evidence call for other high-level prospective trials. LND during RC has shown to be easily performed with a minimally invasive approach (i.e., during robot-assisted RC (RARC)) without differences as compared to a traditional open surgery. Complications related to LND are usually uncommon and do not depend on the template of node dissec tion.